Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01068704 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety of BMS-690514 in Combination With Letrozole to Treat Metastatic Breast Cancer
A Phase 2 study of Breast Cancer, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 2
- Development phase
- 4
- Enrollment target
- 8
- Study locations
NCT01068704: Completed Phase 2 study of Breast Cancer, sponsored by Bristol-Myers Squibb.
NCT01068704 is a Phase 2 study of Breast Cancer that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 4 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (100% lower). The trial reports 8 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01068704, a Phase 2 study of Breast Cancer, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 4 participants
- Enrollment target
- 8
- Study locations
Study Summary
The purpose of this study is to determine if BMS-690514 + letrozole will be more effective than lapatinib + letrozole in patients who have metastatic hormone receptor positive breast cancer after developing progressive disease immediately following adjuvant antiendocrine therapy
Conditions Studied
Interventions
- DRUG Letrozole
- DRUG Lapatinib
- DRUG BMS-690514
Study Locations (8)
Texas
- Texas Oncology-Abilene - Abilene
- Texas Oncology-Beaumont - Beaumont
- Us Oncology Central Pharmacy - Fort Worth
Washington
- Yakima Valley Memorial Hospital/North Star Lodge - Yakima
La Rioja Province
- Local Institution - La Rioja
Santa Fe Province
- Local Institution - Rosario
Colima
- Local Institution - Colima
Lima Province
- Local Institution - Lima
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2010-06 |
| Est. Completion | 2010-12 |
| Phase | Phase 2 |
What the finished NCT01068704 record still lists
NCT01068704 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 4 participants, a relatively small participant target, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (100% lower).
The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 3 interventions - of which Letrozole is the first listed.
NCT01068704 lists 8 locations in 6 states (Texas, Washington, La Rioja Province).
Frequently Asked Questions
What is clinical trial NCT01068704 about?
NCT01068704 is a clinical study titled "Efficacy and Safety of BMS-690514 in Combination With Letrozole to Treat Metastatic Breast Cancer". The purpose of this study is to determine if BMS-690514 + letrozole will be more effective than lapatinib + letrozole in patients who have metastatic hormone receptor positive breast cancer after developing progressive disease immediately following adjuvant antiendocrine therapy
What is the current status of trial NCT01068704?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 4 participants. The study started on 2010-06. Estimated completion is 2010-12.
What conditions does trial NCT01068704 study?
This clinical trial studies the following conditions: Breast Cancer.
What interventions are being tested in trial NCT01068704?
The interventions under investigation include: Letrozole (DRUG), Lapatinib (DRUG), BMS-690514 (DRUG).
Who is sponsoring clinical trial NCT01068704?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01068704 being conducted?
This trial has 8 study locations across Texas, Washington, La Rioja Province, Santa Fe Province, Colima. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01068704's enrollment target sits among peer trials
4 1215th of 1224 higher than 9 of 1,224 other Breast Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBC
RECRUITING · Phase 2
-
The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer
RECRUITING · Phase 2
-
Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC
RECRUITING · Phase 2
-
Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial
RECRUITING · Phase 2
-
Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score
RECRUITING · Phase 2
-
Precision Medicine in Action: Phase II Trial of Response Adaptive Ablative Pre-operative SPBI (RAPS) and Non-operative Sentinel Lymph Node Biopsy in Patients With Early-stage ER+ Breast Cancer: RAPS Trial
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia